THALES
18.9.2023 14:01:30 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced the launch of CipherTrust Cloud Key Management's Hold Your Own Key (HYOK) in Oracle Cloud Infrastructure (OCI) across all 45 Oracle Cloud Regions—including the recently launched Oracle EU Sovereign Cloud—and OCI’s other distributed cloud offerings. To help meet continued customer demand and the accelerated growth of the OCI platform, HYOK will help OCI customers achieve their data sovereignty and other compliance objectives more easily by encrypting data in OCI with keys that are controlled and managed outside of the cloud platform. The new HYOK capabilities expand on existing support for Bring Your Own Key (BYOK) in OCI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918263668/en/
©Thales
According to the 2023 Thales Cloud Security Study, while the world has become cloud-first, operational complexity in cloud environments remains a significant obstacle for organizations. Overall, cloud security awareness has improved, but concerns around securing data are also rising, with over half (55 percent) of security professionals indicating it’s more complex to manage data in the cloud than it is in on-premises environments. As a result, as cloud usage grows, organizations need a new way to effectively secure cloud environments.
The CipherTrust Cloud Key Management integration enables OCI customers to store and manage their encryption keys outside OCI in a virtual or physical appliance that is entirely under their control and outside of the cloud. Customers can also localize their encryption keys wherever they choose and maintain control of their encrypted data in cloud environments. This approach helps address some of the key privacy and data sovereignty requirements organizations face while making it easier to demonstrate compliance to regulators.
The availability of the Thales external key management solution can help accelerate the move of sensitive data into Oracle Cloud Regions by storing the key in a location that is different than the encrypted data. This enables customers to maintain the same process for managing and controlling encryption keys, whether those keys are used on-premises or in the cloud
Thales CipherTrust Cloud Key Management, the industry-leading multi-cloud encryption key lifecycle management solution, alleviates operational barriers across clouds and hybrid environments. The HYOK functionality gives OCI customers the external key management capabilities necessary to navigate today’s cloud-driven landscape and remain in charge of their data, not just in OCI, but across other cloud providers.
Todd Moore, Vice President of Data Security Products at Thales: “Businesses are increasingly shifting away from legacy on-premises deployments and need assistance in moving their data to the cloud while maintaining security and compliance. As the industry leader in external key management, we’re proud to be the first to support HYOK features in OCI, equipping OCI customers with the necessary solutions to be successful in this journey. To further this best-in-class experience for our combined customer base, Thales is also the first supporting vendor for Oracle EU Sovereign Cloud initiatives.”
Jeppe Larsen, Senior Vice President, OCI Security and Identity at Oracle: “We’re dedicated to making OCI the most trusted cloud for security-sensitive workloads, including those in highly regulated regions and industries. Oracle EU Sovereign Cloud helps customers operating in Europe to address their data sovereignty requirements, and the HYOK integration with Thales enhances that offering. In addition, this partnership and integration will benefit U.S. customers in regulated industries such as financial services by enabling them to take full advantage of OCI, with the privacy and security benefits of HYOK from Thales.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. |
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918263668/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom